Details for New Drug Application (NDA): 207619
✉ Email this page to a colleague
The generic ingredient in CABAZITAXEL is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.
Summary for 207619
Tradename: | CABAZITAXEL |
Applicant: | Breckenridge |
Ingredient: | cabazitaxel |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/1.5ML (40MG/ML) | ||||
Approval Date: | Jun 23, 2022 | TE: | RLD: | No |
Complete Access Available with Subscription